Liquid biopsy to predict response to therapy in GeparNuevo trial
Hanna Hübner from the University Hospital in Erlangen is investigating the RNA phenotype of peripheral immune cells in patients enrolled in the GeparNuevo trial for early-stage breast cancer. By studying the circulating immune repertoire, she aims to uncover associations between immune cell profiles and treatment outcomes. This research could provide valuable insights for personalized treatment approaches and the development of immunotherapeutic strategies.
With the educational support of:
